Vedanta Biosciences Advances Microbiome Drugs at ESCMID 2026
CAMBRIDGE, Mass., April 9, 2026 Vedanta Biosciences, a late clinical-stage biopharmaceutical company, has announced new scientific presentations showcasing its...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CAMBRIDGE, Mass., April 9, 2026 Vedanta Biosciences, a late clinical-stage biopharmaceutical company, has announced new scientific presentations showcasing its...
OSAKA, Japan, April 8, 2026 Shionogi & Co., Ltd. presented new real-world clinical data for Fetroja®/Fetcroja® (cefiderocol) at ESCMID...
